Protalix Biotherapeutics Stock Working Capital

PLX Stock

USD 2.36 0.11 4.89%

Protalix Biotherapeutics fundamentals help investors to digest information that contributes to Protalix Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Protalix Stock. The fundamental analysis module provides a way to measure Protalix Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protalix Biotherapeutics stock.

	Last Reported	Projected for Next Year
Net Working Capital	34.5 M	17.7 M
Change In Working Capital	811 K	1.3 M

Change In Working Capital is likely to rise to about 1.3 M in 2025, whereas Net Working Capital is likely to drop slightly above 17.7 M in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Protalix Biotherapeutics Company Working Capital Analysis

Protalix Biotherapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Protalix Biotherapeutics Working Capital

34.46 M

Most of Protalix Biotherapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protalix Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Protalix Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Protalix Biotherapeutics is extremely important. It helps to project a fair market value of Protalix Stock properly, considering its historical fundamentals such as Working Capital. Since Protalix Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protalix Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protalix Biotherapeutics' interrelated accounts and indicators.

	Total Assets	Net Debt	Net Receivables	Total Liab	Total Current Assets	Total Stockholder Equity	Retained Earnings	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Cash And Equivalents	Net Working Capital	Capital Stock
Total Assets		-0.21	-0.03	0.54	0.99	0.05	-0.23	0.5	0.56	0.09	0.06	0.5	-0.1	0.31	0.52	0.08	0.16	0.01	0.3	0.17	0.22	0.2
Net Debt	-0.21		0.12	0.23	-0.16	-0.45	-0.34	0.21	-0.28	-0.06	0.08	-0.56	0.14	-0.51	0.18	0.28	-0.33	-0.32	-0.29	-0.45	-0.71	-0.49
Net Receivables	-0.03	0.12		0.06	-0.12	-0.09	-0.6	-0.27	-0.02	0.53	0.22	0.16	0.12	-0.22	0.07	0.45	-0.55	-0.17	-0.12	-0.55	-0.29	-0.45
Total Liab	0.54	0.23	0.06		0.52	-0.76	-0.11	0.39	0.45	0.32	-0.31	0.3	0.38	-0.5	0.61	-0.28	0.04	0.32	-0.49	0.29	-0.08	0.19
Total Current Assets	0.99	-0.16	-0.12	0.52		0.07	-0.2	0.5	0.57	-0.04	0.06	0.37	-0.11	0.32	0.57	0.08	0.15	0.02	0.29	0.2	0.24	0.23
Total Stockholder Equity	0.05	-0.45	-0.09	-0.76	0.07		-0.1	-0.13	-0.13	-0.33	0.44	-0.02	-0.54	0.8	-0.3	0.35	0.06	-0.4	0.74	-0.26	0.2	-0.15
Retained Earnings	-0.23	-0.34	-0.6	-0.11	-0.2	-0.1		0.06	-0.03	-0.27	-0.57	0.07	-0.2	0.04	-0.15	-0.87	0.73	0.62	-0.11	0.78	0.52	0.73
Short Term Debt	0.5	0.21	-0.27	0.39	0.5	-0.13	0.06		0.08	0.08	0.0	0.28	-0.2	0.03	-0.01	-0.15	0.39	-0.2	0.22	0.08	-0.22	0.06
Common Stock	0.56	-0.28	-0.02	0.45	0.57	-0.13	-0.03	0.08		0.16	-0.36	0.28	0.17	0.06	0.38	-0.16	-0.08	0.42	-0.02	0.44	0.51	0.63
Accounts Payable	0.09	-0.06	0.53	0.32	-0.04	-0.33	-0.27	0.08	0.16		0.08	0.61	0.35	-0.14	-0.19	0.04	-0.13	-0.09	-0.12	-0.03	-0.19	-0.13
Short Term Investments	0.06	0.08	0.22	-0.31	0.06	0.44	-0.57	0.0	-0.36	0.08		-0.05	-0.22	0.34	-0.25	0.69	-0.29	-0.76	0.47	-0.49	-0.34	-0.65
Property Plant Equipment	0.5	-0.56	0.16	0.3	0.37	-0.02	0.07	0.28	0.28	0.61	-0.05		-0.11	0.27	-0.15	-0.24	0.47	0.03	0.24	0.28	0.21	0.25
Current Deferred Revenue	-0.1	0.14	0.12	0.38	-0.11	-0.54	-0.2	-0.2	0.17	0.35	-0.22	-0.11		-0.44	0.19	0.07	-0.52	0.22	-0.43	0.04	-0.09	-0.04
Net Tangible Assets	0.31	-0.51	-0.22	-0.5	0.32	0.8	0.04	0.03	0.06	-0.14	0.34	0.27	-0.44		-0.26	0.17	0.27	-0.28	0.62	0.06	0.29	0.05
Long Term Debt	0.52	0.18	0.07	0.61	0.57	-0.3	-0.15	-0.01	0.38	-0.19	-0.25	-0.15	0.19	-0.26		-0.05	-0.15	0.38	-0.29	0.15	0.2	0.16
Capital Surpluse	0.08	0.28	0.45	-0.28	0.08	0.35	-0.87	-0.15	-0.16	0.04	0.69	-0.24	0.07	0.17	-0.05		-0.71	-0.72	0.35	-0.82	-0.42	-0.72
Short Long Term Debt	0.16	-0.33	-0.55	0.04	0.15	0.06	0.73	0.39	-0.08	-0.13	-0.29	0.47	-0.52	0.27	-0.15	-0.71		0.18	0.21	0.58	0.28	0.5
Long Term Debt Total	0.01	-0.32	-0.17	0.32	0.02	-0.4	0.62	-0.2	0.42	-0.09	-0.76	0.03	0.22	-0.28	0.38	-0.72	0.18		-0.51	0.73	0.68	0.73
Net Invested Capital	0.3	-0.29	-0.12	-0.49	0.29	0.74	-0.11	0.22	-0.02	-0.12	0.47	0.24	-0.43	0.62	-0.29	0.35	0.21	-0.51		-0.17	0.15	-0.03
Cash And Equivalents	0.17	-0.45	-0.55	0.29	0.2	-0.26	0.78	0.08	0.44	-0.03	-0.49	0.28	0.04	0.06	0.15	-0.82	0.58	0.73	-0.17		0.73	0.88
Net Working Capital	0.22	-0.71	-0.29	-0.08	0.24	0.2	0.52	-0.22	0.51	-0.19	-0.34	0.21	-0.09	0.29	0.2	-0.42	0.28	0.68	0.15	0.73		0.8
Capital Stock	0.2	-0.49	-0.45	0.19	0.23	-0.15	0.73	0.06	0.63	-0.13	-0.65	0.25	-0.04	0.05	0.16	-0.72	0.5	0.73	-0.03	0.88	0.8

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Protalix Biotherapeutics

Working Capital Over Time

Protalix Capital Surpluse

Capital Surpluse

272.01 Million

At this time, Protalix Biotherapeutics' Capital Surpluse is fairly stable compared to the past year.

Based on the company's disclosures, Protalix Biotherapeutics has a Working Capital of 34.46 M. This is 91.9% lower than that of the Biotechnology sector and 93.6% lower than that of the Health Care industry. The working capital for all United States stocks is 97.67% higher than that of the company.

Protalix Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protalix Biotherapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protalix Biotherapeutics could also be used in its relative valuation, which is a method of valuing Protalix Biotherapeutics by comparing valuation metrics of similar companies.

Protalix Biotherapeutics is currently under evaluation in working capital category among its peers.

Protalix Biotherapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Protalix Biotherapeutics from analyzing Protalix Biotherapeutics' financial statements. These drivers represent accounts that assess Protalix Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protalix Biotherapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	105.8M	36.7M	66.4M	120.2M	136.4M	129.5M
Enterprise Value	151.9M	31.2M	82.8M	122.8M	122.1M	116.0M

Protalix Biotherapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Protalix Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Protalix Biotherapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Protalix Fundamentals

	Return On Equity	0.0764
	Return On Asset	0.031
	Profit Margin	0.05 %
	Operating Margin	0.40 %
	Current Valuation	154.85 M
	Shares Outstanding	78.03 M
	Shares Owned By Insiders	13.70 %
	Shares Owned By Institutions	5.98 %
	Number Of Shares Shorted	5.05 M
	Price To Earning	(1.23) X
	Price To Book	4.06 X
	Price To Sales	3.45 X
	Revenue	53.4 M
	Gross Profit	29.08 M
	EBITDA	6.52 M
	Net Income	2.93 M
	Cash And Equivalents	17.11 M
	Cash Per Share	0.41 X
	Total Debt	5.53 M
	Current Ratio	1.33 X
	Book Value Per Share	0.57 X
	Cash Flow From Operations	8.67 M
	Short Ratio	8.40 X
	Earnings Per Share	0.04 X
	Price To Earnings To Growth	(0.10) X
	Target Price	14.5
	Beta	0.73
	Market Capitalization	184.16 M
	Total Asset	73.42 M
	Retained Earnings	(378.39 M)
	Working Capital	34.46 M
	Current Asset	59.65 M
	Current Liabilities	10.33 M
	Net Asset	73.42 M

About Protalix Biotherapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Protalix Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protalix Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protalix Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC